Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: vitamin D

New Insights into CD8+ T Cells & Lupus

Lara C. Pullen, PhD  |  July 6, 2021

A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CD8+ T CellsSLEsystemic lupus erythematosus (SLE)

Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

Jason Liebowitz, MD, FACR  |  June 1, 2021

An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumheartSarcoidosisVitamin D

Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease

Jason Liebowitz, MD, FACR  |  May 24, 2021

Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumIBDinflammatory bowel disease (IBD)

Case Report: Warfarin-Induced Non-Uremic Calciphylaxis Mimicking Vasculitis

Marie Dardeno, DO, Joshua D. Sparling, MD, & William Monaco, MD  |  May 13, 2021

Calciphylaxis, or calcific uremic arteriolopathy, is a rare disease characterized by calcification of the arterioles and capillaries in the dermis and subcutaneous tissue, resulting in thrombus formation and subsequent skin ischemia and necrosis.1 This serious condition most commonly occurs in patients with end-stage renal disease (ESRD) requiring dialysis or in kidney transplant recipients. In rare…

Filed under:ConditionsVasculitis Tagged with:calciphylaxiscase reportEnd-stage renal diseasewarfarin

Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

Sarah F. Keller, MD, & Marcy B. Bolster, MD  |  May 13, 2021

It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbone mineral density (BMD)Osteoporosiszoledronic acid

Osteoporosis Experts Discuss Bisphosphonate Holidays

Susan Bernstein  |  November 24, 2020

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2020bisphosphonatesbone mineral density (BMD)drug holidayFracturesOsteoporosis

Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

Thomas R. Collins  |  July 7, 2020

Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)chronic kidney diseaseEULARfracture riskFractureskidneyOsteoporosisosteoporosis treatments

Preventing the Onset of Rheumatoid Arthritis: Is It Possible?

Jason Liebowitz, MD, FACR  |  June 16, 2020

ACR BEYOND LIVE—A moonshot concept in rheumatology has long been centered on the question of whether autoimmune disease can be cured. A less frequently posed inquiry, albeit equally important, is: Can the onset of autoimmune disease be prevented in the first place? At the 2020 ACR State-of-the-Art Clinical Symposium, Kevin Deane, MD, PhD, associate professor…

Filed under:Rheumatoid Arthritis

After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk

Lisa Rapaport  |  June 15, 2020

(Reuters Health)—Patients hospitalized for a hip fracture are less likely to experience a subsequent fracture-related hospitalization if they start anti-osteoporosis medication sooner, a Taiwanese study suggests.1 Researchers examined data on 77,930 patients aged 50 years and older hospitalized for hip fractures, including 9,986 people prescribed anti-osteoporosis medications within one year of the index fracture. Compared…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:drug treatmentFracturesOsteoporosisosteoporosis treatments

People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19

Carolyn Crist  |  June 15, 2020

NEW YORK (Reuters Health)—People with rheumatic diseases should continue their medicines, monitor their health and avoid stress when possible during the current coronavirus pandemic, according to a group of rheumatologists in South Korea.1 Because rheumatic diseases are linked with chronic inflammation and abnormal immune functions, patients may be at a greater risk for COVID-19 infection,…

Filed under:Conditions Tagged with:COVID-19ExercisePatientswellness

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 24
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences